SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001213900-24-012726 from OS Therapies Inc (OSTX)

OS Therapies Inc
Date: Feb. 12, 2024 · CIK: 0001795091 · Accession: 0001213900-24-012726

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-271034

Date
February 12, 2024
Author
Boustead Securities, LLC
Form
CORRESP
Company
OS Therapies Inc

Letter

Re: OS Therapies Incorporated

February 12, 2024

VIA EDGAR

Division of Corporation Finance

U.S. Securities & Exchange Commission

100 F Street, NE

Washington, DC 20549

Attention: Office of Life Sciences

Registration Statement on Form S-1

File No. 333-271034

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and the other underwriters, hereby join in the request of OS Therapies Incorporated that the effective date of the above-referenced registration statement be accelerated so as to permit it to become effective at 5:00 p.m., Eastern time, on Wednesday, February 14, 2024, or as soon thereafter as practicable.

Pursuant to 460 under the Act, we wish to advise you that the underwriters have distributed as many copies of the preliminary prospectus dated January 24, 2024 to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such preliminary prospectus.

The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
Boustead Securities, LLC

Show Raw Text
CORRESP
1
filename1.htm

February 12, 2024

VIA EDGAR

Division of Corporation Finance

U.S. Securities & Exchange Commission

100 F Street, NE

Washington, DC 20549

Attention: Office of Life Sciences

 Re: OS Therapies Incorporated

Registration Statement on Form S-1

File No. 333-271034

Ladies and Gentlemen:

Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and
the other underwriters, hereby join in the request of OS Therapies Incorporated that the effective date of the above-referenced registration
statement be accelerated so as to permit it to become effective at 5:00 p.m., Eastern time, on Wednesday, February 14, 2024, or as soon
thereafter as practicable.

Pursuant to 460 under the
Act, we wish to advise you that the underwriters have distributed as many copies of the preliminary prospectus dated January 24, 2024
to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such preliminary prospectus.

The undersigned advises
that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

    Very truly yours,

    Boustead Securities, LLC

    By:
    /s/ Keith Moore

    Name:
    Keith Moore

    Title:
    Chief Executive Officer

    As representative of the underwriters